SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The revenue slipped marginally during the December 2023 quarter. A decline of about Rs. 5203.90 millions was observed as compared to Rs. 5234.80 millions during the corresponding quarter last year.The Company's Net profit for the December 2023 quarter have declined marginally to Rs. 232.30  millions as against Rs. 241.50 millions reported during the corresponding quarter ended.Operating profit surged to 528.60 millions from the corresponding previous quarter of 496.80 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202312 202212 % Var 202312 202212 % Var 202303 202203 % Var
Sales 5203.90 5234.80 -0.59 16288.70 16299.00 -0.06 22171.10 21840.20 1.52
Other Income 83.80 66.40 26.20 225.50 168.50 33.83 255.70 320.40 -20.19
PBIDT 528.60 496.80 6.40 2039.90 1475.80 38.22 2520.90 2883.20 -12.57
Interest 43.00 47.00 -8.51 126.90 115.90 9.49 164.70 82.90 98.67
PBDT 485.60 449.80 7.96 1913.00 1359.90 40.67 2356.20 2661.00 -11.45
Depreciation 163.20 117.30 39.13 464.30 340.30 36.44 461.30 432.60 6.63
PBT 322.40 332.50 -3.04 1448.70 1019.60 42.09 1894.90 2228.40 -14.97
TAX 90.10 91.00 -0.99 376.40 272.50 38.13 495.10 571.80 -13.41
Deferred Tax 27.30 -7.30 -473.97 56.50 -4.30 -1413.95 32.50 1.70 1811.76
PAT 232.30 241.50 -3.81 1072.30 747.10 43.53 1399.80 1656.60 -15.50
Equity 587.10 587.10 0.00 587.10 587.10 0.00 587.10 587.10 0.00
PBIDTM(%) 10.16 9.49 7.03 12.52 9.05 38.31 11.37 13.20 -13.87

IOL Chem & Pharma Share Price

91.16 5.66 (6.62%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×